Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OCX 191

Next Previous
Drug Profile

OCX 191

Alternative Names: 3-AP; 3-Apct; NSC 663249; NSC#663249; NTO-1151; OCX-0191; OCX-191; Triapine

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University
  • Developer National Cancer Institute (USA); National Resilience; Trethera; Vion Pharmaceuticals
  • Class Antineoplastics; Pyridines; Small molecules; Thiosemicarbazones
  • Mechanism of Action Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gynaecological cancer
  • Phase II Cervical cancer; Solid tumours
  • No development reported Breast cancer; Cholangiocarcinoma; Gallbladder cancer; Haematological malignancies; Head and neck cancer; Leukaemia; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
  • Discontinued Cancer; Cancer metastases; Hepatitis B; Herpes simplex virus infections; HIV infections

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for phase-I development in Neuroendocrine-tumours(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 02 Jun 2023 Efficacy and adverse events data from the phase III NRG GY006 trial in Gynaecological cancer presented at 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 14 Apr 2023 Safety, efficacy and pharmacokinetics data from phase I trial in Neuroendocrine tumours was presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top